KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Emergent BioSolutions (EBS) EBITDA Margin: 2010-2024

Historic EBITDA Margin for Emergent BioSolutions (EBS) over the last 15 years, with Dec 2024 value amounting to -10.42%.

  • Emergent BioSolutions' EBITDA Margin rose 1115.00% to 33.10% in Q3 2025 from the same period last year, while for Sep 2025 it was 15.02%, marking a year-over-year increase of 3055.00%. This contributed to the annual value of -10.42% for FY2024, which is 5881.00% up from last year.
  • Emergent BioSolutions' EBITDA Margin amounted to -10.42% in FY2024, which was up 84.95% from -69.23% recorded in FY2023.
  • In the past 5 years, Emergent BioSolutions' EBITDA Margin ranged from a high of 27.80% in FY2020 and a low of -69.23% during FY2023.
  • Moreover, its 3-year median value for EBITDA Margin was -15.21% (2022), whereas its average is -31.62%.
  • In the last 5 years, Emergent BioSolutions' EBITDA Margin tumbled by 5,401bps in 2023 and then spiked by 5,881bps in 2024.
  • Emergent BioSolutions' EBITDA Margin (Yearly) stood at 27.80% in 2020, then crashed by 855bps to 19.25% in 2021, then slumped by 3,446bps to -15.21% in 2022, then crashed by 5,401bps to -69.23% in 2023, then surged by 5,881bps to -10.42% in 2024.